Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies
For individuals with advanced prostate cancer, it is important to monitor both PSA decline and any impacts on health-related quality of life. These results will help doctors and other healthcare professionals have a better understanding of patients' cancer experience and the impact of their treatment.<b>Clinical Trial Registration:</b> NCT01946204 (SPARTAN) and, NCT02489318 (TITAN) (ClinicalTrials.gov).
Authors
- Kim N. Chi (ORCID: https://orcid.org/0000-0002-3782-7226)
- Eric Jay Small (ORCID: https://orcid.org/0000-0003-3191-6268)
- Byung Ha Chung (ORCID: https://orcid.org/0000-0001-9817-3660)
- Lawrence I. Karsh (ORCID: https://orcid.org/0000-0002-3095-8303)
- Sabine Brookman‐May (ORCID: https://orcid.org/0000-0003-2967-4028)
- Fred Saad (ORCID: https://orcid.org/0000-0003-2986-5617)
- Stéphane Oudard (ORCID: https://orcid.org/0000-0003-0893-285X)
- Katherine B. Bevans (ORCID: https://orcid.org/0000-0003-0145-7945)
- Sharon McCarthy (ORCID: https://orcid.org/0000-0002-7299-5129)
- Matthew R. Smith (ORCID: https://orcid.org/0000-0001-5207-2370)
- Neeraj Agarwal
Institutions
- Harvard University (US)
- University of California, San Francisco (US)
- Yonsei University (KR)
- Université Paris Cité (FR)
- University of Utah (US)
- Huntsman Cancer Institute (US)
- Massachusetts General Hospital (US)
- The Urology Center of Colorado (US)
- Hôpital Européen Georges-Pompidou (FR)
- Centre Hospitalier de l’Université de Montréal (CA)
- Gangnam Severance Hospital (KR)
- Janssen (United States) (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Future Oncology
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1080/14796694.2024.2384257
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00